After Reaching Milestone, Is Adaptimmune Therapeutics Plc – American Depositary (NASDAQ:ADAP)’s Short Interest Revealing Something?

June 16, 2018 - By Vivian Park

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Logo

The stock of Adaptimmune Therapeutics Plc – American Depositary (NASDAQ:ADAP) registered an increase of 19.74% in short interest. ADAP’s total short interest was 1.45 million shares in June as published by FINRA. Its up 19.74% from 1.21M shares, reported previously. With 362,500 shares average volume, it will take short sellers 4 days to cover their ADAP’s short positions. The short interest to Adaptimmune Therapeutics Plc – American Depositary’s float is 3.15%.

The stock increased 2.12% or $0.26 during the last trading session, reaching $12.51. About 398,602 shares traded. Adaptimmune Therapeutics plc (NASDAQ:ADAP) has risen 151.13% since June 16, 2017 and is uptrending. It has outperformed by 138.56% the S&P500.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. The company has market cap of $1.18 billion. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients. It currently has negative earnings. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings Coverage

Among 3 analysts covering Adaptimmune Therapeutics (NASDAQ:ADAP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adaptimmune Therapeutics had 3 analyst reports since March 16, 2018 according to SRatingsIntel. The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) earned “Buy” rating by Cowen & Co on Friday, March 16. On Friday, March 16 the stock rating was initiated by Leerink Swann with “Buy”.

More news for Adaptimmune Therapeutics plc (NASDAQ:ADAP) were recently published by:, which released: “Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self-renewing, and …” on June 11, 2018.‘s article titled: “Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler …” and published on June 01, 2018 is yet another important article.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.